FG-4592
Sponsors
FibroGen, Kyntra Bio, Astellas Pharma Europe B.V.
Conditions
AnemiaAnemia in Chronic Kidney DiseaseAnemia in End Stage Renal DiseaseHealthy Adult SubjectsHealthy SubjectsHepatic InsufficiencyMyelodysplastic SyndromePK for FG-4592
Phase 1
Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects
CompletedNCT01376063
Start: 2010-03-31End: 2010-06-30Updated: 2011-06-20
A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function
CompletedNCT02161224
Start: 2013-09-30End: 2013-12-31Updated: 2014-06-11
A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects
CompletedNCT02161796
Start: 2013-09-30End: 2013-12-31Updated: 2014-06-12
A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects
CompletedNCT02252731
Start: 2013-09-30End: 2013-11-30Updated: 2014-09-30
Phase 2
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
CompletedNCT01596855
Start: 2011-09-30End: 2013-01-31Updated: 2013-02-04
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
CompletedNCT01599507
Start: 2011-12-31End: 2013-01-31Updated: 2014-03-03
Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)
CompletedNCT03303066
Start: 2018-06-06End: 2023-02-08Updated: 2023-05-03
Phase 3
FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease
CompletedNCT02652806
Start: 2015-12-31End: 2017-06-14Updated: 2017-08-24
FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis
CompletedNCT02652819
Start: 2015-12-31End: 2017-06-13Updated: 2017-08-24